Klitzman Robert
College of Physicians and Surgeons, Mailman School of Public Health, Columbia University, Unit 15, 1051 Riverside Drive, New York, NY 10032, USA.
J Genet Couns. 2010 Feb;19(1):68-83. doi: 10.1007/s10897-009-9262-8.
Though the US passed the Genetic Information Non-Discrimination Act, many questions remain of how individuals confronting genetic disease view and experience possible discrimination. We interviewed, for 2 hours each, 64 individuals who had, or were at risk for, Huntington's Disease, breast cancer, or Alpha-1 antitrypsin deficiency. Discrimination can be implicit, indirect and subtle, rather than explicit, direct and overt; and be hard to prove. Patients may be treated "differently" and unfairly, raising questions of how to define "discrimination", and "appropriate accommodation". Patients were often unclear and wary about legislation. Fears and experiences of discrimination can shape testing, treatment, and disclosure. Discrimination can be subjective, and take various forms. Searches for only objective evidence of it may be inherently difficult. Providers need to be aware of, and prepared to address, subtle and indirect discrimination; ambiguities, confusion and potential limitations concerning current legislation; and needs for education about these laws. Policies are needed to prevent discrimination in life, long-term care, and disability insurance, not covered by GINA.
尽管美国通过了《基因信息非歧视法案》,但对于那些面临遗传疾病的个人如何看待以及经历可能存在的歧视,仍存在许多问题。我们对64名患有亨廷顿舞蹈症、乳腺癌或α-1抗胰蛋白酶缺乏症,或有患这些疾病风险的个人进行了每人长达两小时的访谈。歧视可能是隐性的、间接的和微妙的,而非显性的、直接的和公开的;并且难以证明。患者可能会受到“不同”且不公平的对待,这引发了如何定义“歧视”以及“合理便利”的问题。患者往往对立法不清楚且持谨慎态度。对歧视的恐惧和经历会影响检测、治疗和信息披露。歧视可能是主观的,且有多种形式。仅寻找其客观证据可能本身就很困难。医疗服务提供者需要意识到并准备好应对微妙和间接的歧视;当前立法中存在的模糊性、困惑和潜在限制;以及对这些法律进行教育的需求。需要制定政策来防止在《基因信息非歧视法案》未涵盖的生活、长期护理和残疾保险方面的歧视。